Lyell Immunopharma Inc (LYEL)
2.36
-0.23
(-8.88%)
USD |
NASDAQ |
Jun 14, 16:00
2.35
-0.01
(-0.42%)
Pre-Market: 20:00
Lyell Immunopharma Enterprise Value: 75.36M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
June 14, 2024 | 75.36M |
June 13, 2024 | 133.99M |
June 12, 2024 | 126.34M |
June 11, 2024 | 113.60M |
June 10, 2024 | 75.36M |
June 07, 2024 | 93.20M |
June 06, 2024 | 105.95M |
June 05, 2024 | 156.94M |
June 04, 2024 | 108.50M |
June 03, 2024 | 146.74M |
May 31, 2024 | 179.88M |
May 30, 2024 | 151.84M |
May 29, 2024 | 126.34M |
May 28, 2024 | 174.78M |
May 24, 2024 | 179.88M |
May 23, 2024 | 164.59M |
May 22, 2024 | 177.33M |
May 21, 2024 | 139.09M |
May 20, 2024 | 154.39M |
May 17, 2024 | 172.23M |
May 16, 2024 | 182.43M |
May 15, 2024 | 139.09M |
May 14, 2024 | 121.25M |
May 13, 2024 | 85.55M |
May 10, 2024 | 100.85M |
Date | Value |
---|---|
May 09, 2024 | 156.94M |
May 08, 2024 | 111.05M |
May 07, 2024 | 121.25M |
May 06, 2024 | 121.25M |
May 03, 2024 | 75.36M |
May 02, 2024 | 85.55M |
May 01, 2024 | 67.70M |
April 30, 2024 | 26.91M |
April 29, 2024 | 47.31M |
April 26, 2024 | 26.91M |
April 25, 2024 | 34.56M |
April 24, 2024 | 60.05M |
April 23, 2024 | 95.75M |
April 22, 2024 | 88.10M |
April 19, 2024 | 42.21M |
April 18, 2024 | 67.70M |
April 17, 2024 | 80.45M |
April 16, 2024 | 88.10M |
April 15, 2024 | 85.52M |
April 12, 2024 | 241.03M |
April 11, 2024 | 151.81M |
April 10, 2024 | 98.27M |
April 09, 2024 | 116.12M |
April 08, 2024 | 31.99M |
April 05, 2024 | 6.497M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-231.76M
Minimum
Sep 20 2023
4.507B
Maximum
Jun 17 2021
726.74M
Average
248.91M
Median
Enterprise Value Benchmarks
GlycoMimetics Inc | -14.33M |
Candel Therapeutics Inc | 210.85M |
Eliem Therapeutics Inc | 151.26M |
Entrada Therapeutics Inc | 205.30M |
NovaBay Pharmaceuticals Inc | 3.382M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -60.67M |
Revenue (Quarterly) | 0.003M |
Total Expenses (Quarterly) | 55.58M |
EPS Diluted (Quarterly) | -0.24 |
Profit Margin (Quarterly) | -2.02M% |
Earnings Yield | -38.14% |
Normalized Earnings Yield | -35.47 |